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Abstract
Background: Data on complications in children with seasonal influenza virus infection are limited. We initiated a
nation-wide three-year surveillance of children who were admitted to a paediatric intensive care unit (PICU) with
severe seasonal influenza.
Methods: From October 2005 to July 2008, active surveillance was performed using an established reporting
system for rare diseases (ESPED) including all paediatric hospitals in Germany. Cases to be reported were
hospitalized children < 17 years of age with laboratory-confirmed influenza treated in a PICU or dying in hospital.
Results: Twenty severe influenza-associated cases were reported from 14 PICUs during three pre-pandemic
influenza seasons (2005-2008). The median age of the patients (12 males/8 females) was 7.5 years (range 0.1-15
years). None had received vaccination against influenza. In 14 (70%) patients, the infection had been caused by
influenza A and in five (25%) by influenza B; in one child (5%) the influenza type was not reported. Patients spent a
median of 19 (IQR 12-38) days in the hospital and a median of 11 days (IQR 6-18 days) in the PICU; 10 (50%)
needed mechanical ventilation. Most frequent diagnoses were influenza-associated pneumonia (60%), bronchitis/
bronchiolitis (30%), encephalitis/encephalopathy (25%), secondary bacterial pneumonia (25%), and ARDS (25%).
Eleven (55%) children had chronic underlying medical conditions, including 8 (40%) with chronic pulmonary
diseases. Two influenza A- associated deaths were reported: i) an 8-year old boy with pneumococcal
encephalopathy following influenza infection died from cerebral edema, ii) a 14-year-old boy with asthma
bronchiale, cardiac malformation and Addison’s disease died from cardiac and respiratory failure. For nine (45%)
patients, possibly permanent sequelae were reported (3 neurological, 3 pulmonary, 3 other sequelae).
Conclusions: Influenza-associated pneumonia and secondary bacterial infections are relevant complications of
seasonal influenza in Germany. The incidence of severe influenza cases in PICUs was relatively low. This may be
either due to the weak to moderate seasonal influenza activity during the years 2005 to 2008 or due to under-
diagnosis of influenza by physicians. Fifty% of the observed severe cases might have been prevented by following
the recommendations for vaccination of risk groups in Germany.
Background
Influenza belongs to the most frequent vaccine-preven-
table diseases. Clinical manifestations of influenza infec-
tions range from illness with asymptomatic, atypical (i.e.,
gastro-intestinal) or oligosymptomatic disease to severe
toxic progression resulting in death [1,2]. Elderly people
and infants account for the highest morbidity [1,3,4].
Complications of influenza may occur at any age,
affecting most severely patients with chronic underlying
diseases, as chronic pulmonary diseases, diseases of the
circulatory system, metabolic diseases, or immunodefi-
ciency. The most severe complication is peracute fatality
in adolescents and young adults caused by acute circula-
tory failure due to myocarditis or fulminant necrotising
influenza-associated pneumonia. A frequently reported
complication is a secondary bacterial pneumonia. Other
known complications include encephalitis, otitis, and
neuromuscular diseases [1,3,4].
* Correspondence: Streng_A@klinik.uni-wuerzburg.de
1Department of Paediatric Infectious Diseases and Immunology, University
Children’s Hospital, Julius-Maximilians-University, Würzburg, Germany
Full list of author information is available at the end of the article
Streng et al. BMC Infectious Diseases 2011, 11:233
http://www.biomedcentral.com/1471-2334/11/233
© 2011 Streng et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Surveillance studies from several industrialized coun-
tries reported an incidence of paediatric hospitalisations
associated with seasonal influenza of 11-154/100,000
children < 5 years of age, and an incidence of 1-13/
100,000 children treated for influenza in paediatric
intensive care units (PICUs) [5-7]. For the influenza sea-
son 2003-2004, 153 influenza-associated deaths among
children were reported in the United States; 47% of
those occurred in children without underlying chronic
disease [8].
In Germany, only limited epidemiological data on hospi-
talisations and complications of seasonal influenza in chil-
dren is available. In the population-based PRIDE study,
conducted in 11 paediatric practices and 4 hospitals on
children < 3 years of age from November 1999 to October
2001, annual incidence of influenza-associated hospitalisa-
tions was estimated as 120/100,000 [9]. In another popula-
tion-based study conducted 1996-2001 in two paediatric
hospitals, incidence was calculated as 123/100,000 children
< 6 years of age, and 53/100,000 in children < 17 years of
age [10]. However, both studies were too small to detect
rare severe influenza-associated complications and fatal-
ities resulting in PICU admittance.
The objective of this study was the nation-wide detec-
tion of severe influenza virus infections and fatalities in
children, and to identify possible risk factors for complica-
tions. These data are important in the current discussion
of a possible extension of yearly influenza vaccination
from a risk-based strategy to general vaccination of
all children. The study was conducted before the occur-
rence of the new influenza A (H1N1) 2009 pandemic in
Germany.
Methods
Study population
The study population included all children and adoles-
cents < 17 years of age in Germany, with on average
13,166,000 children and adolescents during the years
2005-2008, including on average 3,497,000 children < 5
years of age (German Federal Statistical Office, Germany,
2006-2009).
Reporting system
Prospective, active surveillance to capture severe influ-
enza-associated complications and fatalities was performed
from October 2005 to May 2008, covering three influenza
seasons. Patients fulfilling the study case definition were
included through the Surveillance Unit for Rare Paediatric
Diseases in Germany (ESPED), a nation-wide voluntary
reporting system covering 448 paediatric hospitals and
departments. These hospitals contain approximately
21,500 beds, including about 2,650 paediatric intensive
care beds (National Hospital Statistics, 2008). ESPED
actively collected monthly reports on the occurrence of
severe influenza-associated cases requiring intensive care
treatment from all hospitals. Monthly reporting was
requested even if no cases were identified. For identified
cases, the hospitals were asked to return anonymous,
structured questionnaires on basic demographic character-
istics, underlying chronic medical conditions, influenza
vaccination status, and influenza diagnostics, symptoms,
treatment, pre-defined complications, and sequelae. The
reporting physician filled in the questionnaire according to
the information from the medical chart. If feasible, hospi-
tals provided additionally anonymous medical discharge
letters or autopsy results.
Case definition
All children and adolescents < 17 years of age fulfilling the
following criteria for severe paediatric influenza-associated
infections were included: i) laboratory-confirmed influenza
(antigen test or PCR or virus isolate) within one week
before or after start of influenza symptoms, and ii) hospi-
talisation to a PICU with need for intratracheal/CPAP
ventilation and/or one of the following diagnoses: ence-
phalitis/encephalopathy, bronchitis/bronchiolitis, compli-
cated febrile seizure, acute respiratory distress syndrome
(ARDS), influenza-associated pneumonia, secondary bac-
terial pneumonia, status asthmaticus, sepsis, myocarditis,
apnoea/bradycardia, or iii) influenza-associated death.
Data analysis
All data were entered into a Microsoft Access 2000 data-
base and, after plausibility checks, transferred into SPSS
15.0 for statistical analysis. Data were analysed descrip-
tively (percentages or median with inter-quartile range,
IQR; reported percentages refer to the number of available
data per variable). Comparisons among groups were
assessed for significance (p < 0.05, two-sided) using Pear-
son’s Chi2-test or, where appropriate, Fisher’s Exact test
for categorical data. Continuous data were assessed using
the Mann-Whitney U-test. Due to the small number of
cases per subgroup, the evidence of the statistical compari-
sons was limited.
Ethical considerations
The study was reviewed and approved by the Bavarian
Data Protection Office, Munich, Germany. The institution
agreed that patient informed consent was not needed for
this surveillance study.
Results
Participating study sites and recruitment
Twenty (5%) hospitals reported 29 patients. The report-
ing hospitals were situated in 9 (56%) of the 16 federal
states of Germany. Of the 29 reports, 9 (31%) had to be
excluded from the analysis: for 3 patients, the hospitals
did not provide information on the inclusion criteria,
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3 patients had no laboratory-confirmed influenza diagno-
sis, 1 patient was older than 16 years of age, and 2
patients had been reported twice.
Patient characteristics and duration of hospitalisation
A total of 20 valid patients reported from 14 (4%) hospitals
were identified, 9 (45%) in the season 2005/2006, 6 (30%)
in 2006/2007, and 5 (25%) in 2007/2008. Seasonal distri-
bution peaked in March 2006, and in February 2007 and
2008. Twelve (60%) of the 20 children were male. The
median age was 7.5 years (IQR 0.5-12.75, range < 1 month
to 15 years of age); 9 (45%) children were < 5 years of age,
including 5 (25%) children < 1 year of age.
Duration of hospital stay varied from < 1 to 96 days
(median 19, IQR 12-38), duration of PICU stay was
between < 1 and 50 days (median 11, IQR 6-18). In 70% of
patients, PICU admission occurred at the day of hospital
admission or within one day afterwards (range 0-10 days).
In one child, the influenza infection was assumed to be
nosocomial, with start of influenza symptoms and transfer
to the PICU 9 days after initial hospitalisation due to com-
plicated pneumonia caused by Mycoplasma pneumoniae.
Virological and microbiological diagnostics
There were 14 (70%) cases of seasonal influenza A and 5
(25%) cases of influenza B; in one (5%) patient influenza
infection was confirmed but the influenza type was not
available. Influenza subtypes were determined for 3 sam-
ples, with seasonal influenza A (H1N1) in two patients
and influenza A (H3N2) in one child. Influenza virus
infection was determined by antigen testing in 8 (40%),
PCR in 4 (20%), both antigen testing and PCR in 7 (35%)
patients, and PCR combined with virus isolation in one
(5%) patient. Most frequently, tracheal (30%) or pharyn-
geal (20%) secretions, nasopharyngeal swabs (15%) or a
combination of these materials (20%) were used for diag-
nosis. In 2 (10%) children influenza infection was con-
firmed by serum diagnostics and in one (5%) patient from
lung biopsy material after fatal outcome.
CRP values were available from 18 children (median
8.4 mg/dl, IQR 3.9-23.1). Laboratory-confirmed co-infec-
tions were reported in a total of 13 (65%) children (4 viral,
7 bacterial, 2 fungal; Table 1). Diagnostic analysis for
simultaneous respiratory syncytial virus (RSV) infection
was performed in 10 (50%) children; in 4 with positive
results. All 4 children diagnosed with both influenza and
RSV suffered from pneumonia and/or bronchitis/bronch-
iolitis and needed PICU treatment for a median of 9 days
(IQR 4-13); three were < 1 year of age. Microbiological
diagnostics were performed from blood cultures of
17 (85%) patients (3 positive with Staphylococcus sp.),
from cerebrospinal fluid in 3 (15%) children (one positive
post-mortem with Streptococcus pneumoniae), and
from pleural fluid in 2 (10%) children (1 positive with
Staphylococcus aureus; Table 1). Other positive results
were mainly reported from tracheal aspirates in patients
receiving intratracheal ventilation (Table 1). Of seven
patients with bacterial co-infections, three were infected
with two different bacterial species. Patients with co-infec-
tion by bacteria or fungi were treated at the PICU for a
median of 18 days (IQR 12-30), and, thus, twice as long
compared to patients without such co-infections (median
9 days, IQR 5-11; p = 0.01).
Clinical symptoms, radiological diagnoses and treatment
A total of 158 clinical signs and symptoms at PICU admit-
tance were reported from 18 patients (71 (45%) respira-
tory, 38 (24%) gastro-intestinal, 49 (31%) neurological;
Table 2). The most frequently reported symptoms were
tachypnoea (16), feeding difficulties (15), and fever (15).
A chest radiograph was performed in 17 (85%) and was
abnormal in 16 (80%) patients. Reported radiological diag-
noses were pneumonia (8), ARDS (2), pneumothorax (2),
pleural effusion (2), mediastinal emphysema (1), pericar-
dial effusion (1), and severe pulmonary haemorrhage (1).
Oseltamivir was administered to 10 (50%) children for a
median duration of 5 days (IQR 4.5-5.25); treatment
started in 5 children at the day of PICU admittance, in
one child one day and in 4 children 5-12 days after PICU
admittance. The delay between start of symptoms and
oseltamivir treatment was between 1 and 15 days. A total
of 18 (90%) children were treated intravenously with anti-
biotics, for a median of 13 days (IQR 7-15). Catechola-
mines were administered in 8 (40%) children for a median
of 4 days (IQR 2-14). Inhalation with bronchodilators was
required by 12 (60%) children. A total of 10 (50%) children
needed mechanical ventilation: 4 (20%) received solely
intratracheal ventilation and 2 (10%) CPAP; 4 (20%) chil-
dren received both types of ventilation.
Influenza-associated severe complications and outcome
Thirty-nine severe influenza-associated complications
and two fatalities were reported among the 20 children
(Table 3). The most frequently reported complication
was influenza-associated pneumonia in 12 (60%) patients,
followed by bronchitis/bronchiolitis in 6 patients (30%).
Secondary bacterial pneumonia was observed in 5 (25%)
patients; in 4 cases in combination with influenza-asso-
ciated pneumonia. ARDS was reported in 5 (25%)
patients, all suffering from influenza-associated pneumo-
nia, and in three patients together with sepsis. All 5
patients with ARDS had predisposing underlying chronic
conditions. Encephalitis/encephalopathy occurred in a
total of 5 (25%) patients (including one fatal case), in
three cases in combination with bronchitis/bronchiolitis.
Of the two (10%) reported fatalities, one was an 8-year-
old boy admitted to the PICU with suspected encephalitis
and status epilepticus in 2007. Previously he was
Streng et al. BMC Infectious Diseases 2011, 11:233
http://www.biomedcentral.com/1471-2334/11/233
Page 3 of 7
diagnosed with a delay in speech development and sus-
pected rolandic epilepsy. He received antibiotics, catecho-
lamines, acyclovir and intratracheal ventilation. He was
diagnosed with influenza A one day after PICU admission
and was started on oseltamivir treatment. He died 4 days
after admission from massive cerebral edema. The autopsy
report stated death due to cardiac and circulatory failure.
Streptococcus pneumoniae was diagnosed from PCR analy-
sis of cerebrospinal fluid and brain tissue, indicating ence-
phalopathy following influenza infection complicated by
bacterial superinfection of the CNS. In 2008, a second
fatality was reported from a 13-year-old boy with several
chronic underlying diseases (asthma bronchiale, cardiac
malformation, Addison’s disease). He was found uncon-
scious by his parents after febrile infection during the pre-
vious week. After resuscitation he was transported to the
hospital where he died in the emergency room from car-
diac and respiratory failure. The autopsy report diagnosed
cerebral edema and PCR-confirmed seasonal influenza A
(H1N1) from lung biopsy tissue.
Permanent or possibly permanent sequelae were
described in 2 (10%) and 7 (35%) patients, respectively.
Permanent sequelae were worsening of an underlying
chronic lung disease (BPD) in a patient after influenza A-
associated pneumonia, and post-encephalitic/organic brain
syndrome in a patient with influenza A-associated ence-
phalopathy. Possible permanent sequelae occurred in
5 patients after influenza A and in 2 patients after influ-
enza B. Reported possible sequelae were pulmonary callo-
sity following secondary bacterial pneumonia complicated
by pleural effusion (2 patients), neurological sequelae
(ataxia; severe illness polyneuropathy) following encepha-
lopathy (2 patients), regression in locomotion develop-
ment following PICU treatment for almost 2 months (1
patient), and postural damage after pleural decortication
(1 patient); in one patient the sequelae were not specified.
Underlying chronic conditions and risk factors
Underlying chronic medical conditions were reported in
11 (55%) children, whereby 7 of these had more than
Table 1 Co-infections (viral, bacterial, fungal; culture-confirmed) in children with severe seasonal influenza - Germany,
2005-2008 *
Co-infection Infectious agent Diagnostics/material No. of children (%)
Viral Respiratory Syncytial Virus (RSV) RSV-test (antigen, PCR, or immunofluorescence) 4 (20)
Bacterial - gram positive Staphylococcus aureus Pleural fluid (1), tracheal aspirate (2) 3 (15)
Staphylococcus epidermis Blood culture 2 (10)
Staphylococcus hominis Blood culture 1 (5)
Streptococcus pneumoniae Liquor and brain tissue (post-mortem) 1 (5)
Enterococcus sp. Central venous catheter/blood culture 1 (5)
Bacterial - gram negative Hafnia alvei Tracheal aspirate 1 (5)
Bacterial - mycoplasma-like Mycoplasma pneumoniae. Serology 1 (5)
Fungal Candida albicans Tube tip 1 (5)
Aspergillus sp. Tracheal aspirate 1 (5)
* Data on co-infections reported in 13 (65%) of 20 children; percentages refer to the number of all 20 patients. Multiple nominations were possible. sp: species;
not further specified.
Table 2 Clinical signs and symptoms of severe seasonal
influenza in children at PICU admittance - Germany,
2005-2008*
Clinical signs and symptoms No. of children (%)
Tachypnoea 16 (89)
Cough 14 (78)
Rhinitis 14 (78)
Conjunctivitis 14 (78)
Apnoea 13 (72)
Refusal of food or drink 15 (83)
Diarrhea 12 (67)
Vomiting 11 (61)
Fever ≥ 38°C 15 (83)
Clouding of consciousness 14 (78)
Headache 10 (56)
Pain in the limbs 10 (56)
* Data on symptoms were available from 18 children; percentages refer to the
number of the available patients. Multiple nominations were possible.
Table 3 Severe influenza-associated complications and
fatalities in children treated in PICUs - Germany, 2005-
2008*
Severe complications/death No. of children (%)
Influenza-associated pneumonia 12 (60)
Bronchitis / bronchiolitis 6 (30)
Secondary bacterial pneumonia 5 (25)
Encephalitis / encephalopathy 5 (25)
ARDS 5 (25)
Sepsis 3 (15)
Status asthmaticus 2 (10)
Apnoea / bradycardia 1 (5)
Death 2 (10)
* Data on diagnoses were available from 20 children; percentages refer to the
number of the available patients. Multiple nominations were possible.
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one such condition. Chronic pulmonary diseases were
most frequent and were reported for 8 (40%) children;
three had asthma bronchiale but no other pulmonary
disease, three had possible broncho-pulmonary dysplasia
(BPD) and two had other pulmonary diseases. Further
underlying medical conditions were: cardiac malforma-
tions in 4 (20%), immunocompromised condition in
4 (20%), preterm birth in 2 (10%), and other chronic
conditions in 4 (20%) children (Addison’s disease; Cor-
nelia-De-Lange Syndrome; hereditary motor and sensory
neuropathy (HMSN) and scoliosis; unclear retardation).
Patients with underlying chronic conditions stayed sig-
nificantly longer in the hospital (median 31 days, IQR
18-55) than patients without underlying conditions
(median 13 days, IQR 7-19; p = 0.01). They also tended
to stay longer at the PICU (p = 0.06), and a higher pro-
portion of these children needed mechanical ventilation
(73% vs. 22%, p = 0.07).
Information about the influenza vaccination status was
available from 17 (85%) patients; none had been vacci-
nated against influenza. Out of the 11 children from risk
groups with chronic underlying disease the vaccination
status was not available in 2 (18%) patients, and 1 (9%)
child was < 6 months of age and therefore too young to be
immunized.
Discussion
We describe the results from a nation-wide surveillance
study on severe paediatric seasonal influenza cases in
Germany during three pre-pandemic influenza seasons
between 2005 and 2008. A total of 20 laboratory-con-
firmed influenza-associated PICU cases (14 influenza type
A, 5 type B, 1 type unknown), including two fatalities,
were reported. This number was surprisingly low and cor-
responded to an estimated annual incidence for PICU-
admitted children with seasonal influenza of 0.1/100,000
children < 5 years of age. In contrast, for the same age
group incidences of PICU admissions associated with sea-
sonal influenza were 4/100,000 in USA and 1-13/100,000
in South Australia [5,7]. Apart from country-specific dif-
ferences in access to health care as well as in criteria for
ICU hospitalisation, the lower incidence found in our
study may also be due to the weak to moderate influenza
activity during the observation period in Germany [11].
Another important explanation is possible under-diagnosis
of influenza in the hospitals, as not all physicians perform
influenza testing of children admitted with severe acute
respiratory infection. Low participation in the voluntary
reporting system due to frequent changes of the medical
staff in the PICUs is a further possible reason. Hence, the
low reported incidence for PICU-admitted influenza cases
in this study may underestimate the true incidence of
severe paediatric influenza cases in Germany. With regard
to fatal paediatric cases it should be noted that our study
was not designed to capture influenza-associated fatalities
that occurred outside PICUs, e.g. at home or during emer-
gency treatment. For comparison, the national mortality
register reported a total of 25 influenza-associated (ICD-
10 code J10) deaths in children < 15 years of age during
the years 2006 to 2008.
Our study showed that in Germany children < 1 year of
age and children with chronic underlying diseases are the
main paediatric risk groups for severe seasonal influenza
infections. Influenza-associated pneumonia, secondary
bacterial infections, ARDS and encephalitis/encephalopa-
thy were frequent complications. The observed clinical
characteristics were similar to the results from the U.S.
and other countries [2,4,8,12-17]. However, children in
our study were older (median 7.5 years) than in an ICU
study in the U.S. (median 1.5 years) [12]. Fatalities also
were reported only in two older children (8 and 14 years
of age), whereas the majority of reported paediatric fatal-
ities in the U.S. and Australia are below 5 years of age
[14,17]. In our study, ARDS occurred in 25% of the PICU
children, in contrast to a retrospective chart review in an
U.S. children’s hospital with 27 PICU children diagnosed
with seasonal influenza 2008/2009 [18], which reported
only 4% of ARDS.
In the current study, 10 (50%) patients were treated with
oseltamivir, whereby in 5 (25%) patients treatment was
started several days after the appearance of influenza
symptoms or ICU admission. Antiviral treatment is most
beneficial when started within 2 days after onset of symp-
toms. Nevertheless, oseltamivir treatment initiated later
than 2 days after the first influenza symptoms is still con-
sidered useful in children with influenza pneumonia or to
reduce viral shedding in the hospital [19]; it also seems to
reduce the risk of secondary bacterial super-infections,
although the mechanisms are not fully understood [13]. In
our study, co-infection with more than one bacterial spe-
cies was found only in patients that did not receive oselta-
mivir treatment.
In total, 35% of the patients suffered from bacterial
co-infection, including one fatality associated with
Streptococcus pneumoniae. Patients with bacterial or
fungal co-infections stayed twice as long (median 18
days) at the PICU than other influenza patients, thus
indicating the high influence of those co-infections on
the morbidity. Staphylococcus aureus was the most
frequently observed bacterial species. The data from
Germany indicate a similar situation as observed on
severe paediatric influenza cases (fatalities) in the USA,
which showed bacterial co-infections in 34% of
patients in 2007, most frequently with Staphylococcus
aureus [13].
In Germany, influenza vaccination in children is cur-
rently recommended for risk groups, defined by chronic
underlying diseases. In 2005, a regional survey in children
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< 24 months of age showed that 5% of all children had
been vaccinated against influenza [20]. Among the severe
cases reported in our study no child had been vaccinated.
Eleven (55%) belonged to risk groups with chronic
underlying disease, including eight (40%) of at least two
years of age for whom influenza vaccines are considered
to be efficacious [21]. One risk group child was below 6
months of age and, hence, too young to be immunized.
Two other risk group children were under two years of
age; for this age group, the efficacy of the inactivated
influenza vaccines licensed in Germany is unclear, and
data on safety are insufficient thus far [21]. Forty-five% of
the patients with severe influenza were previously healthy
children, who would not be covered by a risk-based vac-
cination strategy. A recommendation to vaccinate healthy
children routinely against seasonal influenza is not wide-
spread in Europe, but has been argued to have potential
community benefits [22].
Renewed interest in paediatric influenza arose with the
occurrence of the new pandemic influenza A (H1N1) 2009
in Germany from April 2009 onwards [23]. An ongoing
ESPED study on children with severe pandemic influenza
A (H1N1) 2009 reported 93 cases below 15 years of age
from 55 PICUs during a single season (August 2009 to
April 2010), including 15 fatalities (11 within PICUs) [24].
This high number of cases reported in the ongoing ESPED
study may be partly due to an increased awareness in phy-
sicians regarding the new subtype of influenza with
unclear severity at the start of the pandemic, resulting in
more frequent laboratory testing and diagnosis of influ-
enza [5,24]. Additionally, the higher number of PICU
admissions may be due to a truly higher severity of the
pandemic influenza A (H1N1) 2009 subtype in children
compared to previous seasonal influenza subtypes [e.g.,
[18,25]], although not all studies report such a difference
in severity [26,27], or found a difference only regarding
risk groups [28]. Thus, a comparison of both ESPED stu-
dies on the absolute number of severe influenza cases [24]
has to be regarded with caution, and may underestimate
the importance of severe seasonal influenza caused by
non-pandemic influenza virus subtypes in children in Ger-
many. Further prospective, laboratory-confirmed surveil-
lance in PICUs is needed to clarify the complication rates
associated with influenza virus A and B and their different
subtypes and lineages.
Conclusions
Almost half of the children with severe complications
associated with seasonal influenza were previously
healthy children, for whom there is currently no recom-
mendation to vaccinate against influenza. Fifty% were
children with chronic diseases for whom vaccination
had been recommended but had not been followed. In
these children the severe course of disease might have
been prevented by vaccination. Oseltamivir treatment
was often started several days after start of influenza
symptoms or PICU admission, indicating that influenza
is often diagnosed too late for effective antiviral patient
treatment. The general incidence of influenza-associated
severe disease in German PICUs was very low, but
under-diagnosis and under-reporting during these pre-
pandemic influenza seasons may be likely. Therefore
prospective studies providing influenza subtype screen-
ing on PICU admissions of children with respiratory dis-
ease are needed to assess more accurately the burden of
severe influenza-associated complications. These studies
are necessary to provide data and evidence for the dis-
cussion on influenza prevention by general routine vac-
cination in children.
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